Zijian Rao

Structure-based rational design enables efficient discovery of a new selective and potent AKT PROTAC degrader.

Xiaowu Dong, Yizhe Wu, J. Che, 2022, European journal of medicinal chemistry.

One therapeutic approach for triple-negative breast cancer: Checkpoint kinase 1 inhibitor AZD7762 combination with neoadjuvant carboplatin.

Qiaojun He, Bo Yang, Ji Cao, 2021, European journal of pharmacology.

A practical "preTACs-cytoblot" platform accelerates the streamlined development of PROTAC-based protein degraders.

Li Jiang, Qiaojun He, Xiaowu Dong, 2023, European journal of medicinal chemistry.